Q2 Earnings Forecast for Inogen Issued By B. Riley

Inogen, Inc (NASDAQ:INGN - Free Report) - Analysts at B. Riley issued their Q2 2025 earnings per share estimates for shares of Inogen in a report issued on Sunday, June 15th. B. Riley analyst A. Schock expects that the medical technology company will post earnings of ($0.22) per share for the quarter. B. Riley has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Inogen's current full-year earnings is ($1.73) per share. B. Riley also issued estimates for Inogen's Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.

Several other equities analysts also recently weighed in on INGN. Stifel Nicolaus cut their target price on Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen downgraded Inogen from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC raised Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price on the stock in a research report on Thursday, May 22nd.

Inogen Trading Up 0.6%

Shares of NASDAQ INGN traded up $0.04 during trading hours on Wednesday, hitting $6.64. 342,887 shares of the company traded hands, compared to its average volume of 242,526. The stock has a market capitalization of $178.55 million, a price-to-earnings ratio of -5.77 and a beta of 1.64. The company's 50 day moving average price is $6.63 and its 200 day moving average price is $8.23. Inogen has a 12 month low of $5.70 and a 12 month high of $13.33.

Inogen (NASDAQ:INGN - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.27. The firm had revenue of $82.28 million for the quarter, compared to the consensus estimate of $79.57 million. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%.

Hedge Funds Weigh In On Inogen

A number of large investors have recently bought and sold shares of INGN. Ieq Capital LLC purchased a new position in Inogen during the 4th quarter valued at $94,000. Bank of New York Mellon Corp boosted its holdings in Inogen by 23.5% during the 4th quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company's stock valued at $1,160,000 after acquiring an additional 24,082 shares during the period. AlphaQuest LLC purchased a new position in Inogen during the 4th quarter valued at $43,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Inogen by 42.5% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 248,822 shares of the medical technology company's stock valued at $2,282,000 after acquiring an additional 74,197 shares during the period. Finally, Monaco Asset Management SAM boosted its holdings in Inogen by 104.0% during the 4th quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company's stock valued at $702,000 after acquiring an additional 39,000 shares during the period. Hedge funds and other institutional investors own 89.94% of the company's stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.